Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
View Patent ↗Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.
1. A crystalline Form I of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate, characterized by an x-ray powder diffraction pattern having having peaks expressed as 2Θ at:
i) one or both of 17.48 and 20.58 ±0.20 degrees when measured against an internal silicon standard; and
ii) at least four peaks selected from a group of peaks consisting of: 4.50, 9.04, 14.60, 15.14, 15.80, 16.60, 18.16, 18.44, 19.48, 21.74 and 25.46±0.20 degrees when measured against an internal silicon standard.
2. The crystalline Form I of claim 1 , characterized by an x-ray powder diffraction pattern, wherein at least six peaks are selected from the group of peaks.
3. The crystalline Form I of claim 1 , characterized by an x-ray powder diffraction pattern, wherein at least eight peaks are selected from the group of peaks.
4. The crystalline Form I of claim 1 , characterized by an x-ray powder diffraction pattern, wherein all of the peaks are selected from the group of peaks.
5. A pharmaceutical composition comprising the crystalline Form I.
6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Alzheimer's disease.
7. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Schizophrenia.
8. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Alzheimer's disease.
9. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia.
10. A pharmaceutical composition comprising the crystalline Form I of claim 2 .
11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Alzheimer's disease.
12. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Schizophrenia.
13. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Alzheimer's disease.
14. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia.
15. A pharmaceutical composition comprising the crystalline Form I of claim 3 .
16. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Alzheimer's disease.
17. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Schizophrenia.
18. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Alzheimer's disease.
19. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia.
20. A pharmaceutical composition comprising the crystalline Form I of claim 4 .
21. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Alzheimer's disease.
22. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Schizophrenia.
23. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Alzheimer's disease.
24. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia.